AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting

ABBVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia . "We are dedicated to transforming standards of care for people living with blood cancers," said Mohamed Zaki M.D., Ph.D, vice president and global head of oncology development, AbbVie. "The data we are presenting at the ASH Annual Meeting build on ...

Related Keywords

Italy ,Germany ,Georgia ,United States ,Atlanta ,Austria ,Canada ,Switzerland ,Italian ,American ,Mohamed Zaki ,Obinutuzumab Clb ,Venetoclax Rituximab Ven ,Instagram ,Janssen Biotech Inc ,Genentech ,Abbvie Company ,Linkedin ,Twitter ,American Society Of Hematology ,Us National Library Of Medicine ,Allergan ,Abbvie Inc ,Facebook ,National Comprehensive Cancer Network ,Macrophage Properties Journal Of Immunology Baltimore ,Outcomes Research ,Exchange Commission ,Youtube ,Development Of Novel Anti ,Roche Group ,American Society ,Annual Meeting ,Line Treatment ,Plus Venetoclax ,Chronic Lymphocytic Leukemia ,Year Post Randomization Disease Free Survival ,Results From ,Minimal Residual Disease ,Combination Small Molecules ,Prospective Data ,Versus Chlorambucil Plus Obinutuzumab ,First Line Treatment ,Unfit Patients ,Dosing Frequency ,Oral Oncolytics ,Refill Adherence Among Patients ,Hematological Malignancies ,Lymphoid Malignancies ,World Registry ,Overall Survival Results ,Combination With Bortezomib ,Refractory Multiple Myeloma ,Plasma Cell Dyscrasias ,Clinical Prospective Therapeutic Trials ,Poor Risk Cytogenetics ,Venetoclax Combined ,Hypomethylating Agents ,Acute Myeloid Leukemia ,Molecular Markers ,Response Prediction ,Observed Across Mutational Spectrum ,Myelodysplastic Syndromes ,High Risk Myelodysplastic Syndrome ,Gilteritinib Demonstrates Molecular Clearance ,Acute Myeloid Leukemias ,Commercially Available Therapies ,Excluding Transplantation ,Refractory Myelodysplastic Syndrome ,High Risk ,Preliminary Efficacy From ,Expansion Cohort ,Venetoclax Plus Daratumumab ,Daratumumab Plus Bortezomib ,Patients With ,Multiple Myeloma Therapy ,Adopting New Approaches ,World Management ,Newly Diagnosed Acute Myeloid Leukemia Treated ,Venetoclax Based Regimens ,Sustained Reduction ,Immunosuppressivet Cells ,T Cell Repertoire ,Refractory Multiple Myeloma Patients Treated ,Multiple Myeloma ,Retrospective Analysis ,Real Life Setting ,Combination With Azacitidine ,Outpatient Setting ,Patients With Untreated Acute Myeloid Leukemia ,Venetoclax Plus Obinutuzumab Retreatment ,Relapsed Chronic Lymphocytic Leukemia ,Venetoclax Combinations ,Newly Diagnosed Acute Myeloid Leukemia ,World Evidence ,Healthcare Resources ,Initiating Venetoclax ,Routine Clinical Practice ,Across Canada ,Venetoclax Therapy Subsequent ,Therapy Under Real World Conditions ,Before Initiation ,Venetoclax Therapy ,Untreated Patients ,Clonal Dynamics ,Acquired Mutations ,Randomized Phase ,Fixed Duration Combination Treatment ,Lymphocytic Leukemia ,Clonal Growth Rate ,Previous Treatment ,Slowed Down Following Venetoclax Rituximab ,Model From ,Patients Quality ,Cross Sectional Analysis ,Italian Experience ,First Wave ,Patient Preferences Towards Therapies ,Choice Study ,Response Assessment ,Preliminary Results ,Aggressive Lymphomas ,Prospective Therapeutic Trials ,Refractory Follicular Lymphoma ,Mantle Cell ,Refractory Chronic Lymphocytic Leukemia ,Refractory Non Hodgkin ,Initial Clinical Results ,Human Study ,T Cell Redirecting Antibody ,Immune Therapy ,Janssen Biotech ,Breakthrough Therapy Designations ,Breakthrough Therapy Designation ,Patient Information ,Important Safety Information ,Medication Guide ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Tyrosine Kinase ,North Chicago ,Clinically Utilized ,Directed Antibodies ,Macrophage Properties ,Novel Anti Cd ,Cell Surface ,Cancer Science ,